A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Astegolimab in Patients With Chronic Obstructive Pulmonary Disease
Latest Information Update: 19 Jul 2024
At a glance
- Drugs Astegolimab (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms ALIENTO
- Sponsors Genentech
- 16 Jul 2024 Status changed from recruiting to active, no longer recruiting.
- 01 Jul 2024 Status changed from active, no longer recruiting to recruiting.
- 09 May 2024 Planned End Date changed from 1 Mar 2025 to 29 Apr 2025.